Regenerative medicine: does Erythropoietin have a role?

Giovanni Grasso, Davide Bolignano, Valentina Donato, Antonio Lacquaniti, Valeria Cernaro, Giovanni Grasso, Antonio Lacquaniti, Alessandro Allegra, Giulia Maricchiolo, Alessio Sturiale, Lucrezia Genovese, Antoine Buemi, Alessandro Allegra, Michele Buemi, Susanna Campo

Risultato della ricerca: Articlepeer review

15 Citazioni (Scopus)


Regenerative Medicine, a recent new medical domain, aims to develop new therapies through the stimulation of natural regenerative processes also in human beings. In this field, Erythropoietin (EPO) represents a significant subject of research. Several studies allow the assertion that EPO, in different concentrations, has protective effects mainly on the central nervous system, cardiovascular system and renal tissue. This action is carried out through one of few regenerative activities of human beings: angiogenesis. This mechanism, which involves endothelial stem cells and VEGF (Vascular Endothelial Growth Factor), has been experimentally demonstrated with Recombinant human erythropoietin (rHuEPO) and Darbepoetin, a long-acting EPO derivate. Furthermore, the demonstration of a cardiac production of EPO in Fugu rubripes and in Zebrafish has led cardiologists to "discover" Erythropoietin, postulating a hypothetical role in treatment of cardiovascular disease for this hormone. This is some of the experimental evidence which demonstrates that EPO can be in reason considered an important element of research of Regenerative Medicine and put in the network of drugs able to regenerate tissues and organs. © 2009 Bentham Science Publishers Ltd.
Lingua originaleEnglish
pagine (da-a)2026-2036
Numero di pagine10
Stato di pubblicazionePublished - 2009

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.3000.3004???
  • ???subjectarea.asjc.3000.3002???


Entra nei temi di ricerca di 'Regenerative medicine: does Erythropoietin have a role?'. Insieme formano una fingerprint unica.

Cita questo